Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator Controlled Trial of Flexible-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial

Next Previous
Trial Profile

A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator Controlled Trial of Flexible-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Sep 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brexpiprazole (Primary) ; Antidepressants; Quetiapine
  • Indications Major depressive disorder
  • Focus Registrational; Therapeutic Use
  • Acronyms Delphinus
  • Sponsors Otsuka Pharmaceutical Development & Commercialization

Most Recent Events

  • 19 Sep 2022 Results of post-hoc analysis (NCT01360645, NCT01360632, NCT02196506 & NCT01727726) assessing the effects of adjunctive brexpiprazole on different symptom clusters in major depressive disorder, published in the Journal of Affective Disorders.
  • 01 Oct 2019 Results of pooled analysis assessing the effect of adjunctive brexpiprazole on metabolic parameters and body weight in adults with major depressive disorder using pooled data from 4 short-term studies and 1 long-term extension study (NCT01360645, NCT01360632, NCT02196506, NCT01727726, NCT01360866) published in the Journal of Clinical Psychiatry
  • 02 Dec 2018 Results of post-hoc analysis determining the effect of adjunctive brexpiprazole using pooled data from six randomized studies (NCT01360645, NCT01360632, NCT02196506, NCT01727726, NCT00797966, NCT01052077) published in the International Journal of Neuropsychopharmacology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top